Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes
Start here
Subclinical cholestasis, marked by γ-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss, signals gut dysbiosis and predicts resistance to immune checkpoint blockade. The work links these markers to compromised antitumor immunity and points to biomarker-guided microbiota interventions. It offers an accessible way to identify patients likely to resist immunotherapy.
Excerpted from doi.org
Coverage timeline
Follow the coverage to see the different angles.
- doi.orgBiomarkers of subclinical cholestasis predict cancer immunotherapy outcomes
Subclinical cholestasis, marked by γ-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss, signals gut dysbiosis and predicts resistance to immune checkpoint blockade. The work links these markers to compromised antitumor immunity and points to biomarker-guided microbiota interventions. It offers an accessible way to identify patients likely to resist immunotherapy.
Heat trend for this story
还没有足够的连续观测数据，暂不绘制趋势。